SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia
- Olga Frolova
- , Juliana Benito
- , Chris Brooks
- , Rui Yu Wang
- , Borys Korchin
- , Eric K. Rowinsky
- , Jorge Cortes
- , Hagop Kantarjian
- , Michael Andreeff
- , Arthur E. Frankel
- , Marina Konopleva
Research output: Contribution to journal › Article › peer-review
40
Link opens in a new tab
Scopus
citations